SILO Pharma Return on Equity

SILO Pharma (SILO) currently reports a ROE of -91.52%. That is below the Finance sector average of 24.01%. Use the charts on this page to explore SILO Pharma's ROE history and peer comparisons.

SILO Pharma's ROE of -91.52% is lower than the Finance sector average of 24.01%. That is roughly 481.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but SILO Pharma's current -91.52% should be judged against Finance norms (sector average: 24.01%) and against SILO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -91.52%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Finance average is 24.01%. From there, open related valuation or income-statement pages for SILO Pharma, and consider following SILO for alerts when major investors trade the stock.

SILO Pharma is classified in the Finance sector. On ROE, it currently shows -91.52% versus a sector average near 24.01%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Finance are usually more informative than comparing SILO with unrelated industries.